Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder

Neurochemistry International

Volumn 52, Issue 6, 2008, Pages 1297-1303

  Miller, Christine L ^a   Llenos, Ida C ^b   Cwik, Mary ^a   Walkup, John ^a   Weis, Serge ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

3 Hydroxy anthranilic acid; 3 OH anthranilate; HPLC; Metabolites; Nicotinamide; Psychosis; Suicide; Tryptophan

Indexed keywords

3 HYDROXYANTHRANILIC ACID; KYNURENINE; NICOTINAMIDE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ARTICLE; AUTOPSY; BIPOLAR DISORDER; BRAIN TISSUE; CINGULATE GYRUS; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; NEUROBIOLOGY; NEUROPATHOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

3-HYDROXYANTHRANILIC ACID; ADULT; BIOLOGICAL MARKERS; BIPOLAR DISORDER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GYRUS CINGULI; HUMANS; KYNURENINE; MIDDLE AGED; NIACINAMIDE; PREDICTIVE VALUE OF TESTS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUICIDE; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 40949098991     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2008.01.013     Document Type: Article

References (50)

1. al Mardini H., Harrison E.J., Ince P.G., Bartlett K., and Record C.O. Brain indoles in human hepatic encephalopathy. Hepatology 17 6 (1993) 1033-1040
2. Atlas A., Gisslen M., Nordin C., Lindstrom L., and Schwieler L. Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. 1. Brain Behav. Immun. 21 1 (2007) 86-91
3. Badawy A.A., and Evans M. The regulation of rat liver tryptophan pyrrolase activity by reduced nicotinamide-adenine dinucleotide (phosphate). Biochem. J. 156 2 (1976) 381-390
4. Ball H.J., Sanchez-Perez A., Weiser S., Austin C.J., Astelbauer F., Miu J., McQuillan J.A., Stocker R., Jermiin L.S., and Hunt N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396 1 (2007) 203-213
5. Bodaghi B., Boureau O., Zipeto D., Laurent L., Virelizier J.L., and Michelson S. Role of IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase in the replication of human cytomegalovirus in retinal pigment epithelial cells. J. Immunol. 162 2 (1999) 957-964
6. Brown R.R., Ozaki Y., Datta S.P., Borden E.C., Sondel P.M., and Malone D.G. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDs. Adv. Exp. Med. Biol. 294 (1991) 425-435
7. Cho-chung Y.S., and Pitot H.C. Feedback control of rat liver tryptophan pyrrolase. J. Biol. Chem. 242 6 (1967) 1192-1198
8. Cho-chung Y.S., and Pitot H.C. Regulatory effects of nicotinamide on tryptophan pyrrolase synthesis in rat liver in vivo. Eur. J. Biochem. 3 4 (1968) 401-406
9. Dykens J.A., Sullivan S.G., and Stern A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem. Pharmacol. 36 2 (1987) 211-217
10. Ehrensvard G., Liljekvist J., and Heath R.G. Oxidation of 3-hydroxy-anthranilic acid by human serum. Acta Chem. Scand. 14 (1960) 2081-2088
11. Erhardt S., Schwieler L., and Engberg G. Kynurenic acid and schizophrenia. Adv. Exp. Med. Biol. 527 (2003) 155-165
12. Foster A.C., Collins J.F., and Schwarcz R. On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 22 12A (1983) 1331-1342
13. Gill M. Pigments of fungi (Macromycetes). Nat. Prod. Rep. 16 (1999) 301-317
14. Guillemin G.J., Kerr S.J., Smythe G.A., Armati P.J., and Brew B.J. Kynurenine pathway metabolism in human astrocytes. In: Heuther G., Kochen W., Simat T.J., and Steinhart H. (Eds). Tryptophan, Serotonin and Melatonin: Basic Aspects and Applications (1999), Kluwer Academic/Plenum Publishers, New York 125-131
15. Guillemin G.J., Cullen K.M., Lim C.K., Smythe G.A., Garner B., Kapoor V., Takikawa O., and Brew B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 27 47 (2007) 12884-12892
16. Hankes L.V., Leklem J.E., Brown R.R., and Mekel R.C. Tryptophan metabolism in patients with pellagra: the problem of vitamin B6 activity and feedback control of tryptophan pyrrolase enzyme. Am. J. Clin. Nutr. 24 6 (1971) 730-739
17. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. 79 (1976) 13-21
18. Issa F., Gerhardt G.A., Bartko J.J., Suddath R.L., Lynch M., Gamache P.H., Freedman R., Wyatt R.J., and Kirch D.G. A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia. I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Psychiatry Res. 52 3 (1994) 237-249
19. Jhamandas K.H., Boegman R.J., Beninger R.J., Miranda A.F., and Lipic K.A. Excitotoxicity of quinolinic acid: modulation by endogenous antagonists. Neurotox. Res. 2 (2000) 139-155
20. Knox W.E., and Mehler A.H. The conversion of tryptophan to kynurenine in the liver. J. Biol. Chem. 187 (1950) 419-430
21. Korpi E.R., Kleinman J.E., Goodman S.I., and Wyatt R.J. Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Res. 22 4 (1987) 291-301
22. Lenard N.R., and Dunn A.J. Potential role for nonesterified fatty acids in beta-adrenoceptor-induced increases in brain tryptophan. 1. Neurochem. Int. 46 2 (2005) 179-187
23. Littlejohn T.K., Takikawa O., Skylas D., Jamie J.F., Walker M.J., and Truscott R.J.W. Expression and purification of recombinant human indoleamine 2,3-dioxygenase. Protein Expr. Purif. 19 (2000) 22-29
24. Magni G., Amici A., Emmanuelli M., and Raffaelli N. Enzymology of NAD+ synthesis. Adv. Enzymol. Relat. Areas Mol. Biol. 73 (1999) 135-182
25. Manthey M.K., Pyne S.G., and Truscott J.W. Mechanism of reaction of 3-hydroxyanthranilic acid with molecular oxygen. Biochim. Biophys. Acta 1034 (1990) 207-212
26. Miller C.L., Llenos I.C., Dulay J.R., Barillo M.M., Yolken R.H., and Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol. Dis. 15 3 (2004) 618-629
27. Miller C.L., Llenos I.C., Dulay J.R., and Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res. 1073-1074 (2006) 25-37
28. Muller N., and Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res. 10 2 (2006) 131-148
29. Myint A.M., Kim Y.K., Verkerk R., Park S.H., Scharpé S., Steinbusch H.W., and Leonard B.E. Tryptophan breakdown pathway in bipolar mania. J. Affect. Disord. (2007) (Epub ahead of print)
30. Pfefferkorn E.R., Rebhun S., and Eckel M. Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J. Interferon Res. 6 (1986) 267-279
31. Platten M., Ho P.P., Youssef S., Fontoura P., Garren H., Hur E.M., Gupta R., Lee L.Y., Kidd B.A., Robinson W.H., Sobel R.A., Selley M.L., and Steinman L. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 310 5749 (2005) 850-855
32. Rao M.L., Gross G., Strebel B., Braunig P., Huber G., and Klosterkotter J. Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects. 1. Psychiatry Res. 34 3 (1990) 243-257
33. Ravikumar A., Deepadevi K.V., Arun P., Manojkumar V., and Kurup P.A. Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders. Neurol. India 48 3 (2000) 231-238
34. Ren S., Liu H., Licad E., and Correia M.A. Expression of rat liver tryptophan 2,3-dioxygenase in Escherichia coli: structural and functional characterization of the purified enzyme. Arch. Biochem. Biophys. 333 1 (1996) 96-102
35. Rongvaux A., Andris F., Van Gool F., and Leo O. Reconstructing eukaryotic NAD metabolism. 1. Bioessays 25 7 (2003) 683-690
36. Rosario M., Domingues M., Domingues P., Reis A., Fonseca C., Amado F.M.L., and Ferrer-Correia A.J.V. Identification of oxidation products and free radicals of tryptophan by mass spectrometry. J. Am. Soc. Mass Spectrom. 14 (2003) 406-416
37. Ruddick J.P., Evans A.K., Nutt D.J., Lightman S.L., Rook G.A., and Lowry C.A. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev. Mol. Med. 8 20 (2006) 1-27
38. Sainio E.L. The role of adrenal hormones in the activation of tryptophan 2,3-dioxygenase by nicotinic acid in rat liver. Methods Find. Exp. Clin. Pharmacol. 19 7 (1997) 465-470
39. Schutz G., and Feigelson P. Purification and properties of rat liver tryptophan oxygenase. J. Biol. Chem. 247 17 (1972) 5327-5332
40. Schwarcz R., Tamminga C.A., Kurlan R., and Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann. Neurol. 24 4 (1988) 580-582
41. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., and Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 7 (2001) 521-530
42. Shepard P.D., Joy B., Clerkin L., and Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28 8 (2003) 1454-1462
43. Stadtman E.R., and Berlett B.S. Fenton chemistry. Amino acid oxidation. J. Biol. Chem. 266 26 (1991) 17201-17211
44. Stevens C.O., and Henderson L.M. Beef liver 3-hydroxyanthranilic acid oxidase. J. Biol. Chem. 234 (1959) 1188-1190
45. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45 3 (1993) 309-379
46. Terness P., Bauer T.M., Röse L., Dufter C., Watzlik A., Simon H., and Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J. Exp. Med. 196 4 (2002) 447-457
47. Torrey E.F., Webster M., Knable M., Johnston N., and Yolken R. The Stanley Foundation brain collection and neuropathology consortium. Schizophr. Res. 44 2 (2000) 151-155
48. Tortorella A., Monteleone P., Fabrazzo M., Viggiano A., De Luca L., and Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 44 4 (2001) 167-171
49. Uchida K., Usami M., Bandow H., and Harada I. Characteristics of substrates and inhibitors in binding to rat liver l-tryptophan 2,3-dioxygenase: a Fourier transform infrared and kinetic study. Biochim. Biophys. Acta 1121 (1992) 153-159
50. Yao J., Leonard S., and Reddy R. Altered glutathione redox state in schizophrenia. Dis. Markers 22 1-2 (2006) 83-93